Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498768 | 0.90 | EGLN1 (0.77) | EGLN1ABL1RIN1TDP1NR4A2 | |
| SCHEMBL5270357 | 0.88 | EGLN1 (0.78) | EGLN1DGAT1 | |
| SCHEMBL3499809 | 0.81 | EGLN1 (1.00) | EGLN1NR4A2DGAT1ALDH1A3 | |
| SCHEMBL3499130 | 0.76 | GABRA2 (0.62) | EGLN1 | |
| SCHEMBL3498537 | 0.75 | EGLN1 (0.67) | EGLN1NR4A2ALDH1A3HRH4HRH3 | |
| SCHEMBL3499523 | 0.72 | EGLN1 (0.52) | EGLN1DGAT1 | |
| SCHEMBL3499520 | 0.72 | EGLN1 (0.52) | EGLN1DGAT1 | |
| SCHEMBL19017784 | 0.69 | HRH4 (0.57) | EGLN1ABL1RIN1TDP1NR4A2 | |
| SCHEMBL9247958 | 0.69 | ALDH1A1 (0.58) | EGLN1ALDH1A3 | |
| SCHEMBL3499825 | 0.69 | EGLN1 (0.50) | EGLN1NR4A2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | EGLN1 1231/4885ABL1 3815/4885RIN1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.